Earnings Conference highlights: SIHUAN PHARM (00460.HK) experiences explosive growth in the medical beauty Business, and the Innovative Drugs pipeline enters a commercialization turning point.

Earlier, in early February, SIHUAN PHARM had already announced a profit warning in the market, and recently its annual performance report has officially been released, thus the Earnings Reports have come to light.

Gelonghui FinanceMar 31 01:32 ET

The optimization policy direction for drug central purchasing is a hot topic: overcoming the "Low Stock Price" phenomenon and guiding quality supervision.

① The government work report on March 5 mentioned the need to "optimize the Pharmaceutical and consumables centralized procurement policy"; ② From the overall trend of optimizing the centralized procurement policy, there is a greater emphasis on moderate price reductions and quality supervision, and the concentration of the Industry is expected to further increase.

cls.cnMar 30 19:41 ET

BD Trade resolves financing difficulties! Industry: Innovative Drugs have survived, but the challenge of thriving is even greater.

① In 2024, license-out Trade has become an important way for Biotech to recover funds and increase revenue; ② The quality and standing of Innovative Drugs in China are gaining more international recognition; ③ Whether Innovative Drugs are worth investing in is related to the secondary market in the short term, but in the medium to long term, it depends on the improvement of the primary market exit channels, the payment environment for Innovative Drugs, and other issues.

cls.cnMar 30 09:19 ET

SIHUAN PHARM (00460.HK) announced its annual results, with sales revenue from the medical beauty Business increasing by approximately 65.4%.

On March 17, Glonghui announced that SIHUAN PHARM (00460.HK) achieved total revenue of approximately RMB 1901.1 million for the fiscal year ending December 31, 2024, reflecting an increase of about 2.2% year-on-year. Revenue from the medical beauty Business was approximately RMB 744.2 million, up about 65.4% year-on-year, mainly due to the high market recognition of products during the year, which significantly boosted medical beauty sales revenue, alongside new income generated from product sales. Revenue from Innovative Drugs and Other Pharmaceuticals was approximately RMB 57.6 million, up about 388.1% year-on-year.

Gelonghui FinanceMar 28 00:30 ET

Express News | Sihuan Pharmaceutical Holdings Group FY Pretax Profit RMB -428.3 Million

ReutersMar 28 00:01 ET

Express News | Sihuan Pharmaceutical Holdings Group FY Gross Margin 65.3%

ReutersMar 28 00:01 ET